Navigation Links
ICBS to focus on pharmaceutical and environmental markets
Date:8/5/2009

NEW YORK, MONTREAL, and SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ - ICBS Ltd., (OTCPK: ICBT), board of directors, announced that the company will focus its efforts on the pharmaceutical market through its subsidiary, Canadian Bio Med Systems Ltd., and the environmental market through its partnership with BioSpec Global Solutions Inc., of Quebec.

                       High Interest in a New Approach

"We feel that at this point, we should concentrate on the most promising investments and that is with Canadian Bio Med Systems and BioSpec Global Solutions. We have therefore decided to cease offering business consulting services through our subsidiary, Inter Canadian Business Services along with divesting our interest in Ramapo Valley Brewery" said Dr. George Tsoukas, Chairman.

ICBS has positioned itself with 51% ownership in Canadian Bio Med Systems and 25% interest in BioSpec Global Solutions.

These companies have entered a multi billion dollar market place in recession proof industries.

ICBS will continue to acquire undervalued opportunities in these selective high-growth industries to create value for our shareholders and target partners by combining expertise in both the product and capital markets. Taking interest in companies to align with their long-term interest and help build enduring value for our investors.

Canadian Bio Med Systems, has acquired the licensing rights to two new potentially revolutionary drugs in the billion dollar ophthalmic arena. The drug for the treatment of Glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the University of Arizona. Glaucoma is a prevalent eye disease is one of the leading causes of blindness in the world, and Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for persons aged 80. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.

BioSpec Global Solutions has developed state-of-the-art technologies for rapid, onsite (remote) monitoring of microbial contamination in drinking water, recreational water, agriculture food production, pharmaceuticals and medical applications. TOGS(TM) 9000 instrument is a single test, precision, portable incubator utilizing the patented technology provide on-site testing of microbial contamination in drinking water. Used in conjunction with a chromogenic reagent, it provides an accurate, virtually fool-proof microbial test for field, rural and remote applications in the detection of Total Coliforms and E.coli to WHO standards using globally approved methods (USEPA, AWWA-APHA). The company holds world wide patents

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.


'/>"/>
SOURCE INTER CANADIAN BUSINESS SERVICE
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alzheimers Disease is the Focus of TBSI Annual Neuroscience Symposium
2. Osteotech to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
3. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
4. NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
5. Zimmer Holdings to Present at BMO Capital Markets Ninth Annual Focus on Healthcare Conference
6. AHMC Inc. & AHMC Healthcare Inc. Continue to Focus on Cost-Management
7. Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference
8. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
9. Nfocus Neuromedical Announces European Approval for Novel Guiding Catheter at Society of NeuroInterventional Surgery
10. Ex- White House Drug Spokesman Urges Double Drug Treatment; Bob Weiner and Policy Analyst Zoe Pagonis Highlight Drug Wars Wrong Focus
11. Pennsylvania Insurance Department Examinations to Focus on Health Insurance Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: